Work

Efficacy and Safety of Once-daily Rimegepant 75 mg Orally Disintegrating Tablet for the Short-term Preventive Treatment of Fasting-related Headache (P10-12.010)

Year: 2025

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000210469

Authors: Taoufik Alsaadi, Reem Suliman, Jiyue Yang, Ekta Agarwal, Terence Fullerton, Denise E. Chou, Ed Whalen, Caline El Jadam, Ibrahim Al Qaisi, Youssef Amin, Athra Alkhateri, Kareem Alsaffarini, Lucy Abraham, Zahra Zunaed, Haytham M. Ahmed, Mohamed Fathy, Mohamed Hegab, Nora Vainstein

Institutions: Pfizer (United States), Pfizer (United Kingdom)

Language: English

Topic: Migraine and Headache Studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409237561

FWCI:

Cites:

Cited by:

Related to: 10